179 related articles for article (PubMed ID: 32142368)
1. Lack of Standardization in the Processing and Reporting of Post-Neoadjuvant Breast Cancer Specimens.
Han R; Regpala S; Slodkowska E; Nofech-Mozes S; Hanna W; Parra-Herran C; Lu FI
Arch Pathol Lab Med; 2020 Oct; 144(10):1262-1270. PubMed ID: 32142368
[TBL] [Abstract][Full Text] [Related]
2. Pathologic reporting practices for breast cancer specimens after neoadjuvant chemotherapy-a survey of pathologists in academic institutions across the United States.
Lanjewar S; Patil P; Fineberg S
Mod Pathol; 2020 Jan; 33(1):91-98. PubMed ID: 31383962
[TBL] [Abstract][Full Text] [Related]
3. Processing and Reporting of Breast Specimens in the Neoadjuvant Setting.
Bossuyt V
Surg Pathol Clin; 2018 Mar; 11(1):213-230. PubMed ID: 29413658
[TBL] [Abstract][Full Text] [Related]
4. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group.
Provenzano E; Bossuyt V; Viale G; Cameron D; Badve S; Denkert C; MacGrogan G; Penault-Llorca F; Boughey J; Curigliano G; Dixon JM; Esserman L; Fastner G; Kuehn T; Peintinger F; von Minckwitz G; White J; Yang W; Symmans WF;
Mod Pathol; 2015 Sep; 28(9):1185-201. PubMed ID: 26205180
[TBL] [Abstract][Full Text] [Related]
5. Breast Specimen Processing and Reporting With an Emphasis on Margin Evaluation: A College of American Pathologists Survey of 866 Laboratories.
Guidi AJ; Tworek JA; Mais DD; Souers RJ; Blond BJ; Brown RW
Arch Pathol Lab Med; 2018 Apr; 142(4):496-506. PubMed ID: 29328775
[TBL] [Abstract][Full Text] [Related]
6. [GEFPICS' guidelines for management of breast cancer tissue samples in the neoadjuvant setting].
Maran-Gonzalez A; Franchet C; Duprez-Paumier R; Antoine M; Barlier C; Becette V; Berghian A; Blanc-Fournier C; Brabencova E; Charafe-Jauffret E; Chenard MP; Dauplat MM; Delrée P; Fleury C; Garbar C; Ghnassia JP; Haudebourg J; MacGrogan G; Mathieu MC; Michenet P; Penault-Llorca F; Poulet B; Robin Y; Roger P; Russ E; Treilleux I; Valent A; Verriele V; Vincent-Salomon A; Arnould L; Lacroix-Triki M;
Ann Pathol; 2019 Dec; 39(6):383-398. PubMed ID: 31257035
[TBL] [Abstract][Full Text] [Related]
7. How do we measure a residual tumor size in histopathology (the gold standard) after neoadjuvant chemotherapy?
Apple SK; Suthar F
Breast; 2006 Jun; 15(3):370-6. PubMed ID: 16185870
[TBL] [Abstract][Full Text] [Related]
8. Standardizing Pathologic Evaluation of Breast Carcinoma After Neoadjuvant Chemotherapy.
Sahoo S; Krings G; Chen YY; Carter JM; Chen B; Guo H; Hibshoosh H; Reisenbichler E; Fan F; Wei S; Khazai L; Balassanian R; Klein ME; Shad S; Venters SJ; Borowsky AD; Symmans WF; Ocal IT
Arch Pathol Lab Med; 2022 May; 147(5):591-603. PubMed ID: 35976643
[TBL] [Abstract][Full Text] [Related]
9. The ever-evolving role of pathologists in the management of breast cancer with neoadjuvant treatment: recommendations based on the Spanish clinical experience.
Burgués O; López-García MÁ; Pérez-Míes B; Santiago P; Vieites B; García JF; Peg V
Clin Transl Oncol; 2018 Mar; 20(3):382-391. PubMed ID: 28795336
[TBL] [Abstract][Full Text] [Related]
10. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response.
Rajan R; Poniecka A; Smith TL; Yang Y; Frye D; Pusztai L; Fiterman DJ; Gal-Gombos E; Whitman G; Rouzier R; Green M; Kuerer H; Buzdar AU; Hortobagyi GN; Symmans WF
Cancer; 2004 Apr; 100(7):1365-73. PubMed ID: 15042669
[TBL] [Abstract][Full Text] [Related]
11. Standardizing of Pathology in Patients Receiving Neoadjuvant Chemotherapy.
Bossuyt V; Symmans WF
Ann Surg Oncol; 2016 Oct; 23(10):3153-61. PubMed ID: 27380637
[TBL] [Abstract][Full Text] [Related]
12. The Perfect Pathology Report After Neoadjuvant Therapy.
Marchiò C; Maletta F; Annaratone L; Sapino A
J Natl Cancer Inst Monogr; 2015 May; 2015(51):47-50. PubMed ID: 26063886
[TBL] [Abstract][Full Text] [Related]
13. Pathology of breast carcinomas after neoadjuvant chemotherapy: an overview with recommendations on specimen processing and reporting.
Sahoo S; Lester SC
Arch Pathol Lab Med; 2009 Apr; 133(4):633-42. PubMed ID: 19391665
[TBL] [Abstract][Full Text] [Related]
14. Mammographically directed breast biopsies: a College of American Pathologists Q-Probes study of clinical physician expectations and of specimen handling and reporting characteristics in 434 institutions.
Nakhleh RE; Jones B; Zarbo RJ
Arch Pathol Lab Med; 1997 Jan; 121(1):11-8. PubMed ID: 9111087
[TBL] [Abstract][Full Text] [Related]
15. Breast specimen handling and reporting in the post-neoadjuvant setting: challenges and advances.
Mrkonjic M; Berman HK; Done SJ; Youngson B; Mulligan AM
J Clin Pathol; 2019 Feb; 72(2):120-132. PubMed ID: 30670564
[TBL] [Abstract][Full Text] [Related]
16. American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome.
Carey LA; Metzger R; Dees EC; Collichio F; Sartor CI; Ollila DW; Klauber-DeMore N; Halle J; Sawyer L; Moore DT; Graham ML
J Natl Cancer Inst; 2005 Aug; 97(15):1137-42. PubMed ID: 16077072
[TBL] [Abstract][Full Text] [Related]
17. Pathologic response and long-term follow-up in breast cancer patients treated with neoadjuvant chemotherapy: a comparison between classifications and their practical application.
Corben AD; Abi-Raad R; Popa I; Teo CH; Macklin EA; Koerner FC; Taghian AG; Brachtel EF
Arch Pathol Lab Med; 2013 Aug; 137(8):1074-82. PubMed ID: 23899063
[TBL] [Abstract][Full Text] [Related]
18. Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
Campbell JI; Yau C; Krass P; Moore D; Carey LA; Au A; Chhieng D; Giri D; Livasy C; Mies C; Rabban J; Sarode VR; Singh B; Esserman L; Chen YY
Breast Cancer Res Treat; 2017 Aug; 165(1):181-191. PubMed ID: 28577078
[TBL] [Abstract][Full Text] [Related]
19. Pathologic evaluation of specimens after neoadjuvant chemotherapy in breast cancer: Current recommendations and challenges.
See SHC; Siziopikou KP
Pathol Res Pract; 2022 Feb; 230():153753. PubMed ID: 34990870
[TBL] [Abstract][Full Text] [Related]
20. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma.
Tetzlaff MT; Messina JL; Stein JE; Xu X; Amaria RN; Blank CU; van de Wiel BA; Ferguson PM; Rawson RV; Ross MI; Spillane AJ; Gershenwald JE; Saw RPM; van Akkooi ACJ; van Houdt WJ; Mitchell TC; Menzies AM; Long GV; Wargo JA; Davies MA; Prieto VG; Taube JM; Scolyer RA
Ann Oncol; 2018 Aug; 29(8):1861-1868. PubMed ID: 29945191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
